Showing results (81-90 of 123) with videos related to
Sort By:
Pageof 13
Transplantation and Cellular Therapy|December 30, 2025
Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults with Acute Myeloid Leukemia: A CIBMTR ReportHemalatha G Rangarajan, Deepakbabu Chellapandian, Rasha Atshan, et al.Blood Immunology & Cellular Therapy|May 15, 2026
Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRMYu Akahoshi, Nikolaos Katsivelos, Ioannis E Louloudis, et al.Blood Advances|November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium ReportVanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2022
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic LeukemiaLiora M Schultz, Anne Eaton, Christina Baggott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationMonzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.Transplantation and Cellular Therapy|September 27, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease SeverityIoannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, et al.Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.Transplantation and Cellular Therapy|September 2, 2024
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White PatientsCarlos A Ortega Rios, Muna Qayed, Aaron M Etra, et al.Medrxiv : the Preprint Server for Health Sciences|July 29, 2026
MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHDTara Sebastian, Daniela Weber, Aaron M Etra, et al.Blood Advances|April 20, 2022
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratificationAaron Etra, Stephanie Gergoudis, George Morales, et al.Pageof 13